ClinConnect ClinConnect Logo
Search / Trial NCT04839419

Obesity-hypoventilation in Metabolic Syndrom Patients

Launched by SOS OXYGENE MEDITERRANEE · Apr 6, 2021

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at a condition called obesity-hypoventilation syndrome, which can happen in people with metabolic syndrome. The goal is to see how common this condition is among patients who have metabolic syndrome and are also dealing with obesity. If you or someone you know is between the ages of 65 and 74, has a body mass index (BMI) over 30 (which means they are considered obese), and is not currently using treatments like CPAP or non-invasive ventilation, they might be eligible to participate in the study.

Participants in this trial will help researchers better understand how often obesity-hypoventilation syndrome occurs in this group of patients. It’s important to note that individuals with obstructive respiratory disease or untreated heart problems will not be included in the study. If eligible, participants can expect to contribute to valuable research that could improve care for people facing similar health challenges.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • BMI\>30 kg/m2
  • no treatment with CPAP nor NIV
  • Exclusion Criteria:
  • obstructive respiratory disease
  • non-treated cardiac dysfunction

About Sos Oxygene Mediterranee

SOS Oxygene Mediterranee is a clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative therapies and interventions. With a focus on respiratory health and related conditions, the organization collaborates with healthcare professionals, research institutions, and regulatory bodies to conduct rigorous clinical trials. By prioritizing patient safety and ethical standards, SOS Oxygene Mediterranee aims to contribute valuable insights to the medical community and enhance the quality of care for individuals affected by respiratory diseases. Their commitment to scientific excellence and patient-centered research drives their mission to foster breakthroughs in medical treatment and improve the lives of patients in the Mediterranean region and beyond.

Locations

Bondigoux, , France

Patients applied

0 patients applied

Trial Officials

Mathieu Despeaux, MD

Principal Investigator

Clinique du Chateau de Vernhes

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials